New 1-year results of the MITRAL study bring “important guidance” on balloon-expandable transcatheter heart valve (THV) replacement in high-risk patients undergoing valve-in-valve (ViV), valve-in-annuloplasty ring (ViR) and valve-in-mitral annular calcification (ViMAC) procedures, according to experts.